Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.65 |
| ▸ | MMP9 | P14780 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3106310 | 0.88 | MMP2 (0.62) | MMP2MMP9ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13037010 | 0.87 | MMP2 (0.66) | MMP2MMP9ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3111172 | 0.87 | MMP2 (0.61) | MMP2MMP9ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3114327 | 0.84 | MMP2 (0.58) | MMP2MMP9ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3105251 | 0.82 | MMP2 (0.65) | MMP2MMP9PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL3114064 | 0.82 | MMP2 (0.65) | MMP2MMP9ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3115789 | 0.80 | MMP2 (0.71) | MMP2MMP9ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3099795 | 0.79 | MMP2 (1.00) | MMP2MMP9PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL3108667 | 0.78 | MMP2 (0.98) | MMP2MMP9PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL13036933 | 0.76 | MMP2 (0.77) | MMP2MMP9ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | MMP2 16/4885MMP9 8/4885PKM 2579/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | MMP2 16/4885MMP9 8/4885PKM 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.